Transamerica Financial Advisors Inc. Sells 1,527 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Transamerica Financial Advisors Inc. lowered its stake in Royalty Pharma plc (NASDAQ:RPRX) by 44.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,932 shares of the biopharmaceutical company’s stock after selling 1,527 shares during the period. Transamerica Financial Advisors Inc.’s holdings in Royalty Pharma were worth $50,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of RPRX. Cerity Partners LLC raised its position in Royalty Pharma by 11.1% during the third quarter. Cerity Partners LLC now owns 32,896 shares of the biopharmaceutical company’s stock valued at $931,000 after purchasing an additional 3,291 shares in the last quarter. Bank of Montreal Can raised its holdings in shares of Royalty Pharma by 186.0% during the 3rd quarter. Bank of Montreal Can now owns 445,937 shares of the biopharmaceutical company’s stock worth $12,580,000 after buying an additional 290,019 shares in the last quarter. D.A. Davidson & CO. bought a new stake in shares of Royalty Pharma during the 3rd quarter worth $1,300,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Royalty Pharma by 6.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,972,201 shares of the biopharmaceutical company’s stock valued at $84,084,000 after buying an additional 174,874 shares in the last quarter. Finally, Northwest & Ethical Investments L.P. grew its position in Royalty Pharma by 7.4% in the third quarter. Northwest & Ethical Investments L.P. now owns 27,746 shares of the biopharmaceutical company’s stock valued at $785,000 after acquiring an additional 1,913 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on RPRX. Citigroup reissued a “buy” rating on shares of Royalty Pharma in a report on Friday. TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $41.60.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $31.37 on Monday. The firm has a market capitalization of $18.08 billion, a price-to-earnings ratio of 21.63, a PEG ratio of 2.31 and a beta of 0.47. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The business’s 50-day moving average price is $32.44 and its 200-day moving average price is $28.86. Royalty Pharma plc has a 12 month low of $24.05 and a 12 month high of $34.20.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Equities research analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were paid a $0.22 dividend. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Friday, February 21st. This represents a $0.88 annualized dividend and a dividend yield of 2.81%. Royalty Pharma’s payout ratio is currently 60.69%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.